Live price temporarily unavailable.
Damora Therapeutics (DMRA) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | $39.0M | −$33.6M | −$52.2M | −$61.2M | −$39.9M | −$22.3M | −$210.9M |
| Net income | −$36.5M | −$34.8M | −$51.8M | −$61.6M | −$38.3M | −$21.4M | −$209.8M |
| EPS (diluted) | −$101137.50 | −$4762.50 | −$51.25 | −$60.75 | −$36.08 | −$18.53 | $3.98 |
| Balance sheet | |||||||
| Cash and equivalents | $11.3M | $163.6M | $62.6M | $32.8M | $21.5M | $14.2M | $257.6M |
| Total assets | $56.6M | $171.6M | $122.2M | $73.2M | $38.2M | $17.1M | $260.5M |
| Total liabilities | $8.14M | $6.11M | $4.99M | $11.4M | $5.90M | $1.30M | $20.1M |
| Shareholders' equity | −$71.1M | $165.5M | $117.2M | $61.8M | $32.3M | $15.8M | $240.4M |
| Cash flow | |||||||
| Operating cash flow | −$19.3M | −$38.2M | −$52.3M | −$42.9M | −$36.9M | −$18.6M | −$6.73M |
| Capital expenditure | — | — | $223.0K | $196.0K | — | — | — |
| Free cash flow | — | — | −$52.5M | −$43.1M | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$3.84M | −$7.10M | −$2.60M | −$3.42M | −$3.16M | −$201.7M | −$30.8M | −$35.0M |
| Net income | −$3.88M | −$6.74M | −$2.53M | −$3.44M | −$3.13M | −$200.7M | −$27.8M | −$31.2M |
| EPS (diluted) | −$3.39 | −$5.17 | −$1.92 | −$2.60 | −$2.36 | $10.86 | −$0.62 | −$0.39 |
| Balance sheet | ||||||||
| Cash and equivalents | $19.7M | $14.2M | $11.9M | $10.2M | $7.61M | $257.6M | $532.9M | $540.5M |
| Total assets | $23.4M | $17.1M | $15.4M | $13.7M | $10.7M | $260.5M | $535.4M | $543.6M |
| Total liabilities | $2.44M | $1.30M | $1.66M | $2.74M | $2.73M | $20.1M | $23.8M | $27.6M |
| Shareholders' equity | $20.9M | $15.8M | $13.7M | $11.0M | $8.01M | $240.4M | $511.6M | $516.1M |
| Cash flow | ||||||||
| Operating cash flow | −$3.65M | −$4.94M | −$2.44M | −$2.24M | −$2.62M | $566.0K | −$20.6M | −$21.9M |
From Damora Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Damora Therapeutics in our feed yet.